AR086656A1 - Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a - Google Patents

Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a

Info

Publication number
AR086656A1
AR086656A1 ARP120101958A ARP120101958A AR086656A1 AR 086656 A1 AR086656 A1 AR 086656A1 AR P120101958 A ARP120101958 A AR P120101958A AR P120101958 A ARP120101958 A AR P120101958A AR 086656 A1 AR086656 A1 AR 086656A1
Authority
AR
Argentina
Prior art keywords
aurora
inhibitors
combination
quinasa
mek
Prior art date
Application number
ARP120101958A
Other languages
English (en)
Spanish (es)
Inventor
Arijit Chakravarty
Patrick Vincent
Original Assignee
Millennium Pharm Inc
Takeda California Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Takeda California Inc filed Critical Millennium Pharm Inc
Publication of AR086656A1 publication Critical patent/AR086656A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP120101958A 2011-06-03 2012-06-01 Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a AR086656A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493217P 2011-06-03 2011-06-03
US201261613207P 2012-03-20 2012-03-20

Publications (1)

Publication Number Publication Date
AR086656A1 true AR086656A1 (es) 2014-01-15

Family

ID=47259953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101958A AR086656A1 (es) 2011-06-03 2012-06-01 Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a

Country Status (9)

Country Link
US (1) US9629850B2 (enExample)
EP (1) EP2713727B1 (enExample)
JP (2) JP6263468B2 (enExample)
CN (1) CN103957709A (enExample)
AR (1) AR086656A1 (enExample)
CA (1) CA2837724C (enExample)
TW (1) TW201316991A (enExample)
UY (1) UY34114A (enExample)
WO (1) WO2012167247A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408551B (zh) * 2013-07-25 2015-08-05 苏州明锐医药科技有限公司 阿立塞替的制备方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP2018524292A (ja) * 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
JP7253181B2 (ja) * 2018-12-21 2023-04-06 株式会社Ｎｔｔドコモ 情報処理装置、情報処理方法及びプログラム
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220032607A (ko) * 2020-02-27 2022-03-15 국립대학법인 홋가이도 다이가쿠 항암제를 스크리닝하는 방법 및 췌장암 치료를 위한 키나아제 억제제의 조합 의약
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299080T3 (es) 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
CN101014603B (zh) * 2004-05-14 2014-08-20 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US20100004247A1 (en) 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
CN102216274A (zh) 2008-11-18 2011-10-12 武田药品工业株式会社 (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate

Also Published As

Publication number Publication date
EP2713727A1 (en) 2014-04-09
CN103957709A (zh) 2014-07-30
US9629850B2 (en) 2017-04-25
TW201316991A (zh) 2013-05-01
WO2012167247A1 (en) 2012-12-06
EP2713727A4 (en) 2014-10-22
CA2837724A1 (en) 2012-12-06
JP2014516992A (ja) 2014-07-17
JP2017178969A (ja) 2017-10-05
CA2837724C (en) 2019-10-29
US20140336180A1 (en) 2014-11-13
EP2713727B1 (en) 2021-03-31
JP6263468B2 (ja) 2018-01-17
UY34114A (es) 2013-01-03

Similar Documents

Publication Publication Date Title
AR086656A1 (es) Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
DOP2018000285A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
UY34870A (es) Cristales de sal
IL289553A (en) Pyrrolo[2,3-b]pyrazines as hpk1 inhibitor and the use thereof
CL2012001329A1 (es) Procedimiento de purificacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo-[3,4-b]piridin-3-il] pirimidin-5-il} metilcarbamato de metilo; y el compuesto intermediario que se obtiene.
CO7170166A2 (es) Inhibidores de pi3k delta selectivos
CL2011001361A1 (es) Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios.
MX2019004204A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
GT201400196A (es) Compuestos de heterociclilo
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
CL2008003575A1 (es) Compuestos derivados de 1,5-dihidropirazolo[3,4-d]piridin-4-ona, inhibidores de pde9a; composicion farmaceutica que los comprende; y su uso en el tratamiento y prevencion del alzheimer, parkinson, esclerosis multiple, demencia vascular, esquizofrenia con demencia, entre otras.
BR112013025798A2 (pt) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para o tratamento de câncer e distúrbios de sistema nervoso
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
UY33985A (es) Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida
CL2014000343A1 (es) Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
AP2013007045A0 (en) 6-Cyclobutyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives their use as PDE9A inhibitors
ECSP099775A (es) Terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
NI201800092A (es) 1,5-dihidro-4h-pirazolo [3, 4-d] pirimidin-4-onas y 1,5-dihidro-4h-pirazolo [4, 3-c] piridin-4-onas como inhibidores de pde1
CL2014002847A1 (es) Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal